Skip to main content

Table 3 Safety and tolerability outcome

From: In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

Adverse events

AS + AQ n (%)

AL n (%)

p-value

Overall

88 (40.0)

87 (39.5)

1.00

Specific AEs

 Abdominal pain

18 (8.1)

17 (7.7)

1.00

 Digestive (nausea, vomiting, anorexia, diarrhea)

22 (10.0)

22 (10.0)

0.86

 Cough and rhinitis

23 (10.5)

28 (12.7)

0.55

 Bronchitis

12 (5.4)

13 (5.9)

1.00

 Fever

40 (18.2)

47 (21.4)

0.47

 Headache

16 (7.3)

21 (9.5)

0.49

 Other events

17 (7.7)

12 (5.5)

0.44

 SAE of any cause

1 (0.5)

1 (0.5)

1.00

  1. AE adverse event, SAE serious adverse event, AL artemether lumefantrine, ASAQ artesunate–amodiaquine